Advanced Solid Tumors and Hematological Malignancies Clinical Trial
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TQB2928 Injection in Patients With Advanced Solid Tumors or Hematological Malignancies
TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα and enhances the phagocytosis of cancer cells by macrophages. In preclinical in vivo models, TQB2928 was active against a wide range of solid tumors and hematologic malignancies. This is the first-in-human phase 1 trial of TQB2928 in patients with advanced solid tumors and hematological malignancies.
|Source||Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|
|Status||Not yet recruiting|
|Start date||August 1, 2021|
|Completion date||December 1, 2022|